GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (XSAT:GEAN.TO.2) » Definitions » COGS-to-Revenue

Genetic Analysis AS (XSAT:GEAN.TO.2) COGS-to-Revenue : 0.42 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS COGS-to-Revenue?

Genetic Analysis AS's Cost of Goods Sold for the three months ended in Dec. 2023 was kr1.61 Mil. Its Revenue for the three months ended in Dec. 2023 was kr3.80 Mil.

Genetic Analysis AS's COGS to Revenue for the three months ended in Dec. 2023 was 0.42.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Genetic Analysis AS's Gross Margin % for the three months ended in Dec. 2023 was 57.67%.


Genetic Analysis AS COGS-to-Revenue Historical Data

The historical data trend for Genetic Analysis AS's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Analysis AS COGS-to-Revenue Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.24 0.18 0.19 0.35 0.31

Genetic Analysis AS Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.23 0.16 0.50 0.42

Genetic Analysis AS COGS-to-Revenue Calculation

Genetic Analysis AS's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=4.431 / 14.147
=0.31

Genetic Analysis AS's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.608 / 3.799
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Analysis AS  (XSAT:GEAN.TO.2) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Genetic Analysis AS's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1.608 / 3.799
=57.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Genetic Analysis AS COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genetic Analysis AS's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Analysis AS (XSAT:GEAN.TO.2) Business Description

Traded in Other Exchanges
Address
Kabelgata 8, Oslo, NOR, 0580
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS (XSAT:GEAN.TO.2) Headlines

No Headlines